Oral Systemic Administration of Ankaferd Blood Stopper Has No Short-Term Toxicity in an In Vivo Rabbit Experimental Model


Bilgili H., ÖZDEMİR Ö., Kosar A., Kurt M., KEKİLLİ M., Shorbagi A., ...More

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, vol.16, no.5, pp.533-536, 2010 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 16 Issue: 5
  • Publication Date: 2010
  • Doi Number: 10.1177/1076029609335912
  • Journal Name: CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.533-536
  • Keywords: ankaferd blood stopper, rabbit, toxicity, oral administration, BLEEDING MODEL, EFFICACY
  • Gazi University Affiliated: No

Abstract

Background: Ankaferd blood stopper (ABS) is a standardized herbal extract obtained from 5 different plants. In Turkey, it has been approved for local topical applications in external postsurgical and postdental surgery bleedings. Ankaferd blood stopper, besides its hemostatic activity, has in vitro anti-infectious and antineoplastic actions. Objective: The aim of this study was to assess short-term hematological and biochemical safety following the oral systemic administration of ABS to rabbits. Methods: Twelve rabbits (aged 6-12 months) were included to test the safety of oral ABS. Animals were divided into 4 groups, which had ABS administered orally at doses of 1, 3, 6, and 9 mL, irrespective of their weight. The general well-being and feeding patterns of the animals were observed for a period of 7 days. Blood samples (5.5 mL) were obtained just before oral administration, on days 1 and 4. Results: During the observation period of 7 days, none of the animals showed any abnormal behavior or deviation from the normal. Acute mucosal toxicity, hematotoxicity, hepatotoxicity, nephrotoxicity, and biochemical toxicity were not observed during the short-term follow-up of the animals. Conclusions: No signs of toxicity were observed in rabbits during short-term study with oral ABS administration.